| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| CATALYST PHARMACEUTICALS, INC. | Director | Common Stock, par value $0.001 per share | 0 | $0 | $21.70 | Aug 1, 2025 | Direct |
| CATALYST PHARMACEUTICALS, INC. | Director | Restricted Stock Units | 63.6K | Nov 20, 2025 | Direct | ||
| CATALYST PHARMACEUTICALS, INC. | Director | Options to purchase common stock | 58.1K | Nov 20, 2025 | Direct | ||
| ALX ONCOLOGY HOLDINGS INC | Director | Stock option (right to buy) | 40.4K | Aug 12, 2025 | Direct | ||
| Xilio Therapeutics, Inc. | Director | Stock Option (right to buy) | 31K | Jun 11, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| CPRX | CATALYST PHARMACEUTICALS, INC. | Nov 20, 2025 | 2 | $0 | 4 | Nov 24, 2025 | Director |
| ALXO | ALX ONCOLOGY HOLDINGS INC | Aug 12, 2025 | 1 | $0 | 4 | Aug 13, 2025 | Director |
| ALXO | ALX ONCOLOGY HOLDINGS INC | Aug 12, 2025 | 0 | $0 | 3 | Aug 13, 2025 | Director |
| CPRX | CATALYST PHARMACEUTICALS, INC. | Aug 1, 2025 | 0 | $0 | 3 | Aug 8, 2025 | Director |
| XLO | Xilio Therapeutics, Inc. | Jun 11, 2025 | 1 | $0 | 4 | Jun 12, 2025 | Director |
| XLO | Xilio Therapeutics, Inc. | Jun 14, 2024 | 1 | $0 | 4 | Jun 17, 2024 | Director |
| XLO | Xilio Therapeutics, Inc. | Oct 21, 2021 | 0 | $0 | 3 | Oct 21, 2021 | Director |